RecruitingNCT06710665
Tumor Regression Grade As Predictor of Adjuvant Therapy
Tumor Regression Grade As Predictor of Adjuvant Therapy Benefits in Patients with Esophageal Squamous Cell Carcinoma After Neoadjuvant Therapy
Sponsor
Fujian Medical University Union Hospital
Enrollment
400 participants
Start Date
Oct 1, 2024
Study Type
OBSERVATIONAL
Conditions
Summary
Neoadjuvant therapy followed by surgery is preferred for locally advanced esophageal squamous cell carcinoma, but the necessity of adjuvant therapy remains controversial. Tumor regression grade reflects the response to neoadjuvant therapy and may predict patient prognosis, yet its role in guiding adjuvant therapy remains unexplored.
Eligibility
Min Age: 18 Years
Inclusion Criteria1
- (I) underwent R0 resection with either two-field or three-field lymphadenectomy (II) received neoadjuvant therapy such as preoperative radiotherapy, chemoradiotherapy, or combined immunotherapy (III) had esophageal squamous cell carcinoma pathology.
Exclusion Criteria1
- (I) Patients with incomplete clinical data or follow-up information (II) Diagnosed with multiple primary malignancies
Interventions
DRUGChemotherapy
Chemotherapy
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06710665
Related Trials
A Study of KC1036 in Combination With PD-1 Antibody and Platinum-based Chemotherapy as First-line Treatment in Patients With Advanced Esophageal Cancer
NCT074810581 location
Phase II Study Evaluating Safety and Efficacy of Tislelizumab for Elderly Patients Unfit for Chemotherapy, With Advanced Esophageal Squamous-cell Carcinoma
NCT0720573124 locations
Study of Tislelizumab Combined With Chemoradiotherapy and Surgery for Unresectable Esophageal Squamous Cell Carcinoma
NCT070391628 locations
A First in Human Study of ALX2004 With Advanced or Metastatic Selected Solid Tumors
NCT070850917 locations
177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors
NCT071898712 locations